Exagen Diagnostics, which sells diagnostic blood tests that detect lupus and rheumatoid arthritis, filed on Friday with the SEC to raise up to $69 million in an initial public offering.
Primary shareholders include Sun Mountain Capital, Tullis Health Investors, Joseph Advisory Services, Signal Peak Ventures and Capital Royalty.
The Vista, CA-based company, which was founded in 2002 and booked $6 million in sales for the 12 months ended June 30, 2014, plans to list on the NASDAQ under the symbol EXDX. Exagen Diagnostics initially filed confidentially on August 4, 2014. Leerink Partners and Baird are the joint bookrunners on the deal. No pricing terms were disclosed.
